scholarly journals MON-440 Unusual Case of Metastatic Struma Ovarii Diagnosed at the Time of Hysterectomy

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Jennifer Merrill ◽  
Sara Ahmadi ◽  
Jennifer Perkins
Keyword(s):  
Thyroid Cancer ◽  
Total Thyroidectomy ◽  
Mature Teratoma ◽  
Thyroid Tissue ◽  
Whole Body ◽  
Ovarian Teratoma ◽  
Thyroid Ultrasound ◽  
Struma Ovarii ◽  
Follicular Variant ◽  
Malignant Struma Ovarii

Abstract Introduction: Struma ovarii is rare ovarian teratoma composed of more than 50% mature thyroid tissue, which can rarely transform to malignancy. There are fewer than 200 cases reported and no established treatment approach. We present a case of metastatic malignant struma ovarii. Case Presentation: A 41 year old female was diagnosed with metastatic papillary thyroid carcinoma (PTC) after it was found on uterine histopathology. History was notable for remote left ovarian cystectomy of a mature teratoma with prominent thyroid component. She had no personal or family history of craniocervical radiation or thyroid cancer. Eight years later, she had a total hysterectomy for menorrhagia. Pathology showed subcentimeter serosal deposits of follicular variant PTC, staining positive for thyroglobulin, CK19, and HBME1. Endometrial and cervical pathology were normal; the myometrium had many leiomyomata. Post-hysterectomy TSH was 2.3 (0.34 - 5.66 µIU/mL), and thyroglobulin 44.3 (<=33.0 ng/mL). Thyroid ultrasound showed a 7 mm isoechoic nodule without lymphadenopathy. Whole body PET/CT showed multiple hypermetabolic masses in the pelvic peritoneum and liver. The right ovary had many cystic lesions and was enlarged to 5.3 x 4.5 cm. She underwent partial hepatectomy, oophorectomy, salpingectomy, and omental resection with no residual disease. Pathology showed follicular variant PTC in both ovaries, peritoneum, colonic mesentery, and omentum. Thyroglobulin fell to 6.9 ng/mL 3 weeks later. A 0.2 cm focus of follicular variant PTC with capsular invasion was found on pathology after total thyroidectomy. She underwent radioiodine ablation with 150 mCi. Postablative scan showed residual activity in the thyroid bed and right hemipelvis, but no new foci of activity. CT abdomen showed resolution of perihepatic lesions and thyroglobulin declined further to 0.5 ng/mL. Discussion: A low risk of recurrence (7.5%) has been reported in patients with malignant struma ovarii, with survival rates of 96.7% at 5 years and 84.9% at 20 years, despite a variety of surgical and adjuvant management strategies. Unilateral cystectomy, unilateral salpingo-oophorectomy, or total abdominal hysterectomy and bilateral salpingo-oophorectomy may be sufficient for patients with well differentiated thyroid cancer arising in struma ovarii without metastases. Thyroid ultrasound should be performed to exclude primary thyroid malignancy. Patients with distant metastases may benefit from aggressive treatment including resection of gross abdominal and pelvic disease and total thyroidectomy to facilitate radioactive iodine ablation and surveillance for recurrence. Conclusion: Due to its rarity, there is no consensus on optimal treatment of malignant struma ovarii. More research in this field is warranted.

scholarly journals Malignant Struma Ovarii with Concurrent Thyroid Cancer: Outcomes during and after Pregnancy

2021 ◽  
pp. 1-5
Author(s):  
Sara Donato ◽  
Helder Simões ◽  
Valeriano Leite
Keyword(s):  
Thyroid Cancer ◽  
Thyroid Tissue ◽  
Pelvic Mass ◽  
Pregnant Patient ◽  
Whole Body ◽  
Ovarian Teratoma ◽  
Struma Ovarii ◽  
Pelvic Mri ◽  
Biochemical Evidence

<b><i>Introduction:</i></b> Struma ovarii (SO) is a rare ovarian teratoma characterized by the presence of thyroid tissue in more than 50% of the tumor. Malignant transformation is rare and the most common associated malignancy is papillary thyroid carcinoma (PTC). Pregnancy may represent a stimulus to differentiated thyroid cancer (DTC) growth in patients with known structural or biochemical evidence of disease, but data about malignant SO evolution during pregnancy are rare. We present the first reported case of a pregnant patient with malignant SO and biochemical evidence of disease. <b><i>Case Presentation:</i></b> A previously healthy 35-year-old female diagnosed with a suspicious left pelvic mass on routine ultrasound was submitted to laparoscopic oophorectomy which revealed a malignant SO with areas of PTC. A 15-mm thyroid nodule (Bethesda V in the fine-needle aspiration cytology) was detected by palpation and total thyroidectomy was performed. Histology revealed a 15 mm follicular variant of PTC (T1bNxMx). Subsequently, she received 100 mCi of radioactive iodine therapy (RAIT) with the whole-body scan showing only moderate neck uptake. Her suppressed thyroglobulin (Tg) before RAI was 1.1 ng/mL. She maintained biochemical evidence of disease, with serum Tg levels of 7.6 ng/mL. She got pregnant 14 months after RAIT, and during pregnancy, Tg increased to 21.5 ng/mL. After delivery, Tg decreased to 14 ng/mL but, 6 months later, rose again and reached 31.9 ng/mL on the last follow-up visit. TSH was always suppressed during follow-up. At the time of SO diagnosis, a chest computed tomography scan showed 4 bilateral lung micronodules in the upper lobes which were nonspecific, and 9 months after diagnosis, a pelvic MRI revealed a suspicious cystic nodule located on the oophorectomy bed. These lung and pelvic nodules remained stable during follow-up. Neck ultrasonography, abdominal MRI, and fluorodeoxyglucose-positron emission tomography showed no suspicious lesions. <b><i>Discussion/Conclusion:</i></b> As for DTC, pregnancy seems to represent a stimulus to malignant SO growth. This can be caused by the high levels of estrogen during pregnancy that may bind to receptors in malignant cells and/or by the high levels of hCG which is known to stimulate TSH receptors.

scholarly journals Metastatic malignant struma ovarii with coexistence of Hashimoto’s thyroiditis

2016 ◽  
Vol 2016 ◽  
Author(s):  
Marco Russo ◽  
Ilenia Marturano ◽  
Romilda Masucci ◽  
Melania Caruso ◽  
Maria Concetta Fornito ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Risk Stratification ◽  
Thyroid Tissue ◽  
Surgical Excision ◽  
Disease Diagnosis ◽  
Ovarian Teratoma ◽  
List Type ◽  
Struma Ovarii ◽  
Malignant Struma Ovarii

Summary Struma ovarii is a rare ovarian teratoma characterized by the presence of thyroid tissue as the major component. Malignant transformation of the thyroidal component (malignant struma ovarii) has been reported in approximately 5% of struma ovarii. The management and follow-up of this unusual disease remain controversial. We report the case of a woman with a history of autoimmune thyroiditis and a previous resection of a benign struma ovarii that underwent hystero-annexiectomy for malignant struma ovarii with multiple papillary thyroid cancer foci and peritoneal involvement. Total thyroidectomy and subsequent radioiodine treatment lead to complete disease remission after 104 months of follow-up. The diagnosis and natural progression of malignant struma ovarii are difficult to discern, and relapses can occur several years after diagnosis. A multidisciplinary approach is mandatory; after surgical excision of malignant struma, thyroidectomy in combination with 131I therapy should be considered after risk stratification in accordance with a standard approach in differentiated thyroid cancer patients. Learning points Malignant struma ovarii is a rare disease; diagnosis is difficult and management is not well defined. Predominant sites of metastasis are adjacent pelvic structures. Thyroidectomy and 131I therapy should be considered after risk stratification in accordance with standard approaches in DTC patients.

Papillary thyroid cancer found in struma ovarii: A case report

2013 ◽  
Vol 21 (3-4) ◽  
pp. 141-142
Author(s):  
Ivan Majdevac ◽  
Dejan Lukic ◽  
Milan Ranisavljevic
Keyword(s):  
Thyroid Carcinoma ◽  
Endometrial Carcinoma ◽  
Germ Cells ◽  
Histopathological Examination ◽  
Mature Teratoma ◽  
Thyroid Tissue ◽  
Point Of View ◽  
Struma Ovarii ◽  
Papillary Thyroid ◽  
Malignant Struma Ovarii

Struma ovarii is composed of thyroid tissue originated from germ cells in a mature teratoma. Thyroid carcinoma found in struma ovarii is very rare. Primary thyroid carcinoma should be excluded. We present a 62-year-old female with papillary thyroid carcinoma in a mature teratoma as a incidentally found diagnosis. The patient underwent the surgery because of the endometrial carcinoma, while the histopathological examination found endometrial carcinoma as well as malignant struma ovarii. From the surgical point of view, it is very important to evaluate thyroid gland status in patients with malignant struma ovarii.

scholarly journals SUN-481 A Coexisting Primary Papillary Thyroid Carcinoma in a Case of Malignant Struma Ovarii with Follicular Thyroid Carcinoma: 2 Types of Thyroid Cancer in the Same Patient

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Ghada Elshimy ◽  
Richa Bhattarai ◽  
Kelvin Tran ◽  
Ricardo Rafael Correa
Keyword(s):  
Thyroid Carcinoma ◽  
Total Thyroidectomy ◽  
Follicular Thyroid Carcinoma ◽  
Thyroid Tissue ◽  
Follicular Carcinoma ◽  
Good Prognosis ◽  
Struma Ovarii ◽  
Malignant Struma Ovarii ◽  
Lymph Node Sampling ◽  
Aortic Lymph Node

Abstract Introduction: Struma ovarii is a rare monodermal variant of ovarian teratoma diagnosed when thyroid tissue is more than 50% of the overall tissue. It represents only 1% of all ovarian tumors. The vast majority of struma ovarii are benign (95%); however, malignant tumors have been reported in a small percentage of cases. The most common type is papillary carcinoma(PTC), followed by typical follicular carcinoma found in the pathology after surgical oophorectomy. We report a case of malignant struma ovarii with follicular carcinoma in the setting of additional micro PTC found after total thyroidectomy. Case report: A 48-year-old female presented with right-sided pelvic pain and a mobile pelvic mass. Pelvic MRI showed noted a large complex solid mass with cystic components in the right adnexa. It measured 7.7 x 8.4 x 6.7 cm. Subsequently, the patient underwent a robotic hysterectomy, bilateral salpingo-oophorectomy (TAHBSO), bilateral pelvic and para-aortic lymph node sampling, omentectomy and resection of nodules. Final pathology noted an ovary with struma ovarii with well-differentiated follicular carcinoma, peritoneal nodules containing thyroid tissue and benign lymph nodes. Subsequently, iodine 123 SPECT CT showed physiologic uptake in the thyroid with increased uptake in the pelvis, right perirectal region indicating residual thyroid tissue. The patient underwent total thyroidectomy with radioactive ablation with I131 (154.7 mCi). Pathology detected incidental 0.5mm micro PTC and it was classified as staged pT1aN. 6 months postoperatively, thyroglobulin (Tg) and Tg antibodies were undetectable with no abnormalities found on repeat whole-body scans. The patient has been following up with no new issues for the past 5 years indicating a good prognosis with low risk of recurrence. Discussion and Conclusion: In the literature, Struma ovarii containing thyroid-type carcinoma and papillary or follicular thyroid carcinoma metastasizing to the ovary has been documented. The standard treatment of a patient with malignant struma ovarii is TAHBSO and complete surgical staging, including peritoneal washings for cytology, pelvic and para-aortic lymph node sampling, and omentectomy. In cases with the residual malignant disease after surgery, total thyroidectomy and radioactive ablation are recommended. Our case is a unique case given the presence of 2 different thyroid carcinoma in the same patient. In addition, our patient had multiple risk factors for recurrence including large lesions&gt;4 cm, extra ovarian extension, and the coexisting synchronous primary thyroid cancer, however, she had a good prognosis with no recurrence during the 5 years follow up period.

scholarly journals SUN-LB81 Coexisting Malignant Struma Ovarii and Cervical Follicular Variant Papillary Thyroid Carcinoma

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Jubran Afzal Khan Rind ◽  
Zeb Ijaz Saeed
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Mature Teratoma ◽  
Clinical Endocrinology ◽  
Lymphatic Invasion ◽  
Struma Ovarii ◽  
Papillary Thyroid ◽  
Follicular Variant ◽  
Lower Quadrant ◽  
Malignant Struma Ovarii

Abstract A 44-year-old woman presented with left lower quadrant abdominal pain for 2 months. Further evaluation revealed a left adnexal mass and she underwent a TAH-BSO. A 12 cm mass arising from the left ovary was resected which on microscopy appeared to be papillary thyroid carcinoma follicular variant arising from a mature teratoma (struma ovarii). A thyroid ultrasound showed two subcentimeter right thyroid nodules without any concerning lymphadenopathy. A total thyroidectomy was then performed to allow her to receive adjuvant RAI. The cervical thyroid pathology showed a 0.6 cm follicular variant papillary thyroid carcinoma with negative margins without angioinvasion, lymphatic invasion or extrathyroidal extension. Thyroid hormone suppression with levothyroxine was started. Preoperatively, thyroglobulin was 1381 ng/ml (nl range 1.3-31.8 ng/ml). After TAH-BSO and thyroidectomy, thyroglobulin was undetectable and so was the anti-thyroglobulin antibody. With an undetectable thyroglobulin level, it was decided not to pursue adjuvant RAI and continue TSH suppression with levothyroxine. Simultaneous existence of malignant struma ovarii and cervical papillary thyroid cancer is rare and has a favorable prognosis compared to metastasis to the ovaries from primary cervical thyroid papillary carcinoma. Due to the rarity of this condition, management is not clear or well supported by evidence. Various approaches are suggested by different authors, including thyroidectomy after resection of malignant struma ovarii to facilitate adjuvant RAI, only performing surgical resection of the ovarian tumor in the absence of high risk features or performing thyroidectomy and RAI only in metastatic or recurrent disease. References:1.Aaron Leong, Philip J. R. Roche, Miltiadis Paliouras, Louise Rochon, Mark Trifiro, Michael Tamilia, Coexistence of Malignant Struma Ovarii and Cervical Papillary Thyroid Carcinoma, The Journal of Clinical Endocrinology & Metabolism, Volume 98, Issue 12, 1 December 2013, Pages 4599-46052.Synchronous malignant struma ovarii and papillary thyroid carcinoma Pablo Fernández Catalina,Antonia Rego Iraeta, Mónica Lorenzo Solar, Paula Sánchez Sobrino DOI: 10.1016/j.endoen.2016.08.006

scholarly journals Incidental finding of ovarian teratoma on post-therapy scan for papillary thyroid cancer and impact of SPECT/CT imaging

2011 ◽  
Vol 55 (7) ◽  
pp. 490-493 ◽  
Author(s):  
Anwar Ali Jammah ◽  
Albert Driedger ◽  
Irina Rachinsky
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Photon Emission ◽  
Thyroid Tissue ◽  
Cystic Teratoma ◽  
Whole Body ◽  
Ovarian Teratoma ◽  
Emission Computed Tomography ◽  
Papillary Thyroid

A 41-year old woman post thyroidectomy and neck dissection is presented in this case. She initially presented goiter and an enlarged cervical lymph node. She had no family history of cancer or radiation therapy. She had total thyroidectomy and found to have papillary thyroid cancer (T4N1M0). Histopathology report revealed multifocal classical papillary thyroid carcinoma with lympho-vascular invasion, extra-thyroidal extension, and positive lymph nodes. She was treated with 6.5 Gigabecquerel (GBq) of 131Iodine. Whole-body scan showed uptake in the neck and large focus in the left lower abdomen. Single-photon emission computed tomography SPECT/CT demonstrated a round shaped mass in the left pelvis. Pathology revealed cystic teratoma with benign thyroid tissue (struma ovarii), and no malignancy. Two months later, she had the second treatment with 5.5 GBq 131Iodine. Her follow-up stimulated and non-stimulated thyroglobulin levels were significantly lower, and there was no abnormal uptake in the follow-up scan.

scholarly journals Hyperfunctioning thyroid cancer: a five-year follow-up

2010 ◽  
Vol 54 (1) ◽  
pp. 78-80 ◽  
Author(s):  
Monalisa Ferreira Azevedo ◽  
Luiz Augusto Casulari
Keyword(s):  
Thyroid Cancer ◽  
Papillary Carcinoma ◽  
Thyroid Tissue ◽  
Needle Aspiration ◽  
Whole Body ◽  
Follicular Variant ◽  
Long Term Follow Up ◽  
Hot Thyroid Nodules

Differentiated thyroid cancer rarely occurs in association with hyperfunctioning nodules. We describe a case of a 47-year-old woman who developed symptoms of hyperthyroidism associated with a palpable thyroid nodule. Thyroid scintigraphy showed an autonomous nodule, and fine-needle aspiration biopsy was suggestive of papillary carcinoma. Laboratorial findings were consistent with the diagnosis of hyperthyroidism. The patient underwent thyroidectomy and a papillary carcinoma of 3.0 x 3.0 x 2.0 cm, follicular variant, was described by histological examination. The surrounding thyroid tissue was normal. Postoperatively, the patient received 100 mCi of 131I, and whole body scans detected only residual uptake. No evidence of metastasis was detected during five years of follow-up. Hot thyroid nodules rarely harbor malignancies, and this case illustrated that, when a carcinoma occurs the prognosis seems to be very good with no evidence of metastatic dissemination during a long-term follow-up.

scholarly journals Unusual Case of Malignant Struma Ovarii and Cervical Thyroid Cancer Preceded by Ovarian Teratoma: Case Report and Review of the Literature

2019 ◽  
Vol 2019 ◽  
pp. 1-7 ◽  
Author(s):  
Elias G. Tzelepis ◽  
Elena Barengolts ◽  
Steven Garzon ◽  
Joseph Shulan ◽  
Yuval Eisenberg
Keyword(s):  
Thyroid Cancer ◽  
English Language ◽  
Postoperative Treatment ◽  
Ovarian Teratoma ◽  
Struma Ovarii ◽  
Ablation Therapy ◽  
Malignant Struma Ovarii ◽  
Abdominal Symptoms ◽  
Cancer Review ◽  
Radioiodine Ablation

Objective. To present a rare case of malignant struma ovarii (MSO) and synchronous thyroid cancer, review the medical literature, and present the latest trends in management. Methods. The case of a woman with MSO and concomitant thyroid cancer is presented, including clinical presentation, treatment, and follow-up care. A search of the English-language literature was conducted using MEDLINE and Google Scholar data bases. Results. We found 10 publications (one abstract) describing 10 patients with MSO and concomitant thyroid cancer. Six additional patients were reported by a study that analyzed the SEER (cancer registry) database. The median age of women was 42 years, with the majority of them presenting with abdominal symptoms. Histologically, most tumors were papillary carcinomas in both organs. In 5 patients, there was extrathyroidal tumor extension at time of surgery. Conclusion. MSO can occasionally coexist with highly aggressive eutopic thyroid cancer. Although this concurrence is even rarer than MSO, clinicians should routinely investigate for possible synchronous thyroid cancer in all cases of MSO and also consider aggressive postoperative treatment including thyroidectomy and radioiodine ablation therapy in cases of MSO.

Sign in / Sign up

Export Citation Format

Share Document